A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

NCT06425549

Status	RECRUITING
Phase	Phase 3
Sponsor	UCB Biopharma SRL
Enrollment	168 participants

Key Eligibility Criteria

Inclusion (10)

- Study participant must be 6 to \<18 years of age, inclusive, at the time of signing the informed consent/assent according to local regulation
- Study participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit
- Study participant meets the following at both the Screening and Baseline Visits:
- Body surface area (BSA) affected by PSO e10%
- Investigator's Global Assessment (IGA) score e3 (on a scale from 0 to 4)

... and 5 more (see full listing online)

Exclusion (11)

- Primary failure (no response within 12 weeks) to 1 or more interleukin-17 (IL-17) biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR more than 1 biologic response modifier other than an IL-17
- Study participant has a presence of guttate, inverse, pustular, or erythrodermic PSO or other dermatological condition that may impact the clinical assessment of PSO
- Study participant has a history of inflammatory bowel disease (IBD) or symptoms suggestive of IBD
- History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
- Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)

... and 6 more (see full listing online)

Locations (50 total)

Ps0021 50162, Fountain Valley, California, United States
Ps0021 50161, Los Angeles, California, United States
Ps0021 50196, Northridge, California, United States
... and 47 more locations